Shuxiang Ma

616 total citations
17 papers, 169 citations indexed

About

Shuxiang Ma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Shuxiang Ma has authored 17 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Shuxiang Ma's work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Brain Metastases and Treatment (4 papers). Shuxiang Ma is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Brain Metastases and Treatment (4 papers). Shuxiang Ma collaborates with scholars based in China. Shuxiang Ma's co-authors include Qiming Wang, Zhen He, Yan Huang, Sen Yang, Zhe Zhang, Likun Chen, Yunpeng Yang, Hongle Li, Hongyun Zhao and Jing Han and has published in prestigious journals such as Journal of Clinical Oncology, The Oncologist and Journal of Thoracic Oncology.

In The Last Decade

Shuxiang Ma

16 papers receiving 167 citations

Peers

Shuxiang Ma

ONCOL

PRM

EPIDE

Christopher D’Avella United States

Maite Martínez Aguillo Spain

Anush Mukeriya France

Simona Carnio Italy

Rita Leporati Italy

Marco Banini Italy

H. Al-Eid Saudi Arabia

Shamsuddin Virani United States

Phil Barber United Kingdom

T. Riley United States

Christopher D’Avella United States

Shuxiang Ma

50 ×0.5

ONCOL

80 ×0.8

PRM

66 ×1.9

18 ×0.6

EPIDE

30 ×1.1

Citations per year, relative to Shuxiang Ma Shuxiang Ma (= 1×) peers Christopher D’Avella

Countries citing papers authored by Shuxiang Ma

Since Specialization

Citations

This map shows the geographic impact of Shuxiang Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuxiang Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuxiang Ma more than expected).

Fields of papers citing papers by Shuxiang Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuxiang Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuxiang Ma. The network helps show where Shuxiang Ma may publish in the future.

Co-authorship network of co-authors of Shuxiang Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Shuxiang Ma. A scholar is included among the top collaborators of Shuxiang Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuxiang Ma. Shuxiang Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Chen, Haiyang, Yufeng Wu, Shuxiang Ma, et al.. (2024). High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.. Journal of Clinical Oncology. 42(16_suppl). 8587–8587. 1 indexed citations

Ma, Shuxiang, Zhen He, Lili Wang, et al.. (2024). Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial. EClinicalMedicine. 70. 102543–102543. 13 indexed citations

Chen, Haiyang, Sen Yang, Yufeng Wu, et al.. (2024). High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study. Journal of Thoracic Oncology. 20(1). 65–75. 9 indexed citations

Zhao, Shen, Wei Jiang, Nong Yang, et al.. (2024). Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy. Translational Lung Cancer Research. 13(2). 269–279. 5 indexed citations

Wu, Yufeng, et al.. (2024). A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis. Clinical Lung Cancer. 25(4). 347–353.e1. 1 indexed citations

Huang, Yan, Qitao Yu, Nong Yang, et al.. (2023). Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9080–9080. 2 indexed citations

Wu, Xuan, Zhe Zhang, Shuxiang Ma, et al.. (2022). Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review. Translational Cancer Research. 11(6). 1795–1805.

Liu, Yang, Hongyan Wang, Sen Yang, et al.. (2022). EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. Journal of Thoracic Disease. 14(6). 2254–2267. 9 indexed citations

Li, Hongle, Shuxiang Ma, Zhen He, et al.. (2022). EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives. Biomarker Research. 10(1). 21–21. 41 indexed citations

10.

Ma, Shuxiang, Zhen He, Lili Wang, et al.. (2022). Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.. Journal of Clinical Oncology. 40(16_suppl). 8516–8516. 4 indexed citations

11.

He, Zhen, Junsheng Wang, Li Ding, et al.. (2021). Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial. Translational Lung Cancer Research. 10(2). 889–899. 9 indexed citations

12.

Ma, Shuxiang, Zhen He, Hongyong Fu, et al.. (2020). Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report. Translational Lung Cancer Research. 9(1). 139–143. 8 indexed citations

13.

Chen, Xinru, Xue Hou, Xiao-Xiao Dinglin, et al.. (2020). Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice. Frontiers in Oncology. 10. 581729–581729. 7 indexed citations

14.

He, Zhen, Xuan Wu, Shuxiang Ma, et al.. (2019). Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma. Clinical Lung Cancer. 20(5). e548–e551. 7 indexed citations

15.

Ma, Shuxiang, Ting Zhou, Yan Huang, et al.. (2018). The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Annals of Translational Medicine. 6(11). 201–201. 23 indexed citations

16.

Zhao, Shen, Ting Zhou, Shuxiang Ma, et al.. (2018). Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer. Cancer Medicine. 7(9). 4208–4216. 7 indexed citations

17.

Ma, Shuxiang, Yan Huang, Yunpeng Yang, et al.. (2018). Prevalence of Burnout and Career Satisfaction Among Oncologists in China: A National Survey. The Oncologist. 24(7). e480–e489. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact